Home » Tenders » Americas » USA » Reagents and Controls with Use of Sysmex xn9100-201 System W/ Cellavision Di-60 Tender

Reagents and Controls with Use of Sysmex xn9100-201 System W/ Cellavision Di-60 Tender

Download Documents

DEPT OF DEFENSE has floated a tender for Reagents and Controls with Use of Sysmex xn9100-201 System W/ Cellavision Di-60. The project location is USA and the tender is closing on 14 Jun 2024. The tender notice number is W81K0224Q0069, while the TOT Ref Number is 101899345. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : USA

Summary : Reagents and Controls with Use of Sysmex xn9100-201 System W/ Cellavision Di-60

Deadline : 14 Jun 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 101899345

Document Ref. No. : W81K0224Q0069

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Tender Details

Description

This is a Sources Sought Notice for Tripler Army Medical Center. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of qualified sources and whether or not to conduct this procurement on a competitive basis. The NAICS code is 325413 and the successful vendor must be registered in SAM.gov with this NAICS. Responses to the information requested will assist the Government in determining the appropriate set-aside and acquisition method. The Medical Readiness Contracting Office - Pacific intends to award a Firm, Fixed-Price order for a base period with up to four (4) option periods to the successful offeror using FAR Parts 8 and 12 procedures.

The requirement is for a firm fixed-price contract based on 9, 886 tests per month (Cost Per Reportable Result - CPRR) that includes ALL Food and Drug Administration (FDA) approved reagents to provide the following: fully automated and reportable complete blood count (CBC) with automated differential, nucleated red cell count; body fluid analysis capability (serous, synovial, and cerebrospinal fluid (CSF)) with white blood cell (WBC), red blood cell (RBC) and total nucleated cell counts to include a 2-part WBC differential with every body-fluid analysis; fully reportable reticulated hemoglobin quantification and immature reticulocyte parameters; fully reportable fluorescent platelet parameter to pair with system-s impedance platelet (PLT) technology; fully reportable extended platelet parameters for the determination of thrombopoiesis to aid in the determination platelet engagement, as well as chemotherapy decisions; and immature granulocyte parameter. The requirement will include the use of the Sysmex xN9100-201 fully automated hematology system with xN10 CBC analyzers, SP-50 Automatic Slide Maker/Stainer, RU-20 reagent dilution unit, CellaVision DI-60 digital slide reader, and BT-50 QC Termina...
Active Contract Opportunity Notice ID W81K0224Q0069 Related Notice Department/Ind. Agency DEPT OF DEFENSE Sub-tier DEPT OF THE ARMY Major Command MEDCOM Office W40M MRCO PACIFIC
General Information
Contract Opportunity Type: Sources Sought (Original)
All Dates/Times are: (UTC-10:00) HONOLULU, HAWAII, USA
Original Published Date: May 28, 2024 05:00 pm HST
Original Response Date: Jun 14, 2024 10:00 am HST
Inactive Policy: 15 days after response date
Original Inactive Date: Jun 29, 2024
Initiative: None

Classification
Original Set Aside:
Product Service Code:
NAICS Code: 325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance: USA